藍帆醫療(002382.SZ):上半年預盈33億元-35億元 同比增長431.09%-463.28%
格隆匯7月14日丨藍帆醫療(002382.SZ)披露2021年半年度業績預吿,公司預計2021年1-6月實現歸屬於上市公司股東的淨利潤33億元-35億元,同比增長431.09%-463.28%。業績預增的主要原因系:
1、2021年上半年,新型冠狀病毒肺炎疫情在海外依然比較嚴峻,對防護手套產品的需求持續增長,產品價格及銷量較去年同期均有較大幅度提升,因而對公司業績產生積極影響。
2、根據公司重大資產重組時與業績承諾方藍帆投資及Li Bing Yung、Thomas Kenneth Graham、Wang Dan簽署的《關於CB Cardio Holdings II Limited之盈利預測補償協議》,與北京信聿簽署的《關於CB Cardio Holdings V Limited之盈利預測補償協議》,標的公司CB Cardio Holdings II Limited因未完成2020年度業績承諾,公司於2021年5月17日召開第五屆董事會第十五次會議、第五屆監事會第十四次會議,於2021年6月8日召開2020年年度股東大會審議通過了《關於重大資產重組標的業績補償方案的議案》,公司分別以1元總價回購註銷藍帆投資持有的公司2336.1227萬股股份、北京信聿持有的公司2478.7109萬股股份,藍帆投資和北京信聿同時返還補償股份對應的分紅款分別為317.71萬元和337.10萬元,Li Bing Yung、Thomas Kenneth Graham、Wang Dan分別以現金方式補償公司161.32萬美元、12.88萬美元、9.66萬美元。上述業績補償款及補償股份摺合金額合計約10.95億元,已於6月份實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.